12 Sep
2021

Mobile royalty stack decline; China’s EU SEP snub; New US patent sales data; Oppo v Nokia escalates; Thickets getting worse, says biosimilars IP head; plus much more

Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week

The Long Read

The headline 5G royalty rates set by Nokia, Ericsson and InterDigital materially exceed those they were able to achieve in their 4G programmes, write Ankura's Mike Lasinski, Philip Kline and Alejandra Loaiza-Delgado. Read more here

MONDAY 6 September

Aggregate patent royalty payouts to Qualcomm, Nokia, Ericsson and InterDigital are declining both in absolute terms and as a percentage of smartphone sales, according to a new research report. Read more here

There are different types of AI inventions and patent claims should be structured differently for each to comply with EPO eligibility requirements and to obtain commercially relevant rights. Read more here

TUESDAY 7 September

New research shows that patent activity around business methods is on an uptrend in both Japan and South Korea, and that it has exploded in China. Read more here

Pfizer’s patent portfolio is much smaller than it was after a bonfire of rights between 2011 and 2015 that saw much of its internally generated and acquired IP allowed to lapse. Read more here

A recent UK judgment, overturning the high threshold standard for sufficiency set out in a High Court decision, is good news for owners of patents claiming large numbers of compounds. Read more here

WEDNESDAY 8 September

China has brushed off an EU request for further information on controversial SEP decisions the country’s courts have handed down. Read more here

The latest quarterly US patent sales data from AST shows operating companies involved in most transactions, with deals involving semiconductor and electronic assets leading the way. Read more here

THURSDAY 9 September

Oppo has sued Nokia for patent infringement in China and Germany, expanding the licensing dispute between the two companies. Read more here

Fresenius Kabi’s biosimilars IP head, Rachel Moodie, argues that written description rules and a weak IPR system allow for significant patent thicketing in the US. Read more here

Acting USPTO director Drew Hirshfeld says the agency is looking at potential reforms to discretionary denials, Arthrex director reviews, subject matter eligibility examinations and more. Read more here

FRIDAY 10 September

New patent claims filed against Zhuhai CosMX in the Western District of Texas are the latest example of Chinese battery suppliers coming under greater IP pressure overseas. Read more here

Despite the many flaws in China’s patent subsidy policy, the strategy may have been justified as it helped build a level of IP awareness in the country that otherwise would not exist. Read more here

Why Ericsson’s Fifth Circuit FRAND victory over HTC could mean that SEP owners begin to see the US as a more attractive jurisdiction in which to assert their rights. Read more here

SATURDAY 11 September

The Australian Federal Court's recent DABUS patent decision is a progressive one that recognises the potential for AI-driven life sciences innovation. Read more here

Joff Wild

Author | Editor-in-chief

[email protected]

Joff Wild